ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy.Nature reviews. Clinical oncology · 2023Pooled it
- Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.Nature medicine · 2022Pooled it
- Predicting cancer immunotherapy response from gut microbiomes using machine learning models.Oncotarget · 2022Pooled it
- Association of probiotic use with nivolumab efficacy in gastric cancer patients on gastric acid suppressants.iScience · 2026Article
- Toward a Dual-Axis Model of Microbiome Modulation in Cancer Immunotherapy: Pathobiont Elimination and Functional Ecosystem Restoration.Cellular and molecular bioengineering · 2026Article
- Harnessing the gut microbiota to enhance immune checkpoint inhibitor efficacy: from mechanistic insights to clinical translation.Molecular biology reports · 2026Review
- Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.Annual review of immunology · 2026Review
- HGMT: a database of human gut microbiota for tumors and immunotherapy response.Genome biology · 2025Article
- Microbiome data integration via shared dictionary learning.Nature communications · 2025Article
- Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy.Gastroenterology clinics of North America · 2025Review
- Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis.The Journal of experimental medicine · 2025Article
- Vaginal microbial profile of cervical cancer patients receiving chemoradiotherapy: the potential involvement of Lactobacillus iners in recurrence.Journal of translational medicine · 2024Article
- Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer.Biomarker research · 2024Article
- Gut microbes as medical signature for the effectiveness of immunotherapy in patients with advanced non-small cell lung cancer.Aging medicine (Milton (N.S.W)) · 2024Review
- Gut microbiome for predicting immune checkpoint blockade-associated adverse events.Genome medicine · 2024Article
- Oral vancomycin treatment suppresses gut trypsin activity and preserves intestinal barrier function during EAE.iScience · 2023Article
- The Microbiome in Advanced Melanoma: Where Are We Now?Current oncology reports · 2023Review
- The human microbiome links to prostate cancer risk and treatment (Review).Oncology reports · 2023Review
- Seminars in immunology special issue: Nutrition, microbiota and immunity The unexplored microbes in health and disease.Seminars in immunology · 2023Review
- Intelectin-1 binds and alters the localization of the mucus barrier-modifying bacterium Akkermansia muciniphila.The Journal of experimental medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeWhile immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer by producing durable antitumor responses, only 10%-30% of treated patients respond and the ability to predict clinical benefit remains elusive. Several studies, small in size and using variable analytic methods, suggest the gut microbiome may be a novel, modifiable biomarker for tumor response rates, but the specific bacteria or bacterial communities putatively impacting ICI responses have been inconsistent across the studied populations. EXPERIMENTAL
designWe have reanalyzed the available raw 16S rRNA amplicon and metagenomic sequencing data across five recently published ICI studies (
resultsHerein, we identify novel bacterial signals associated with clinical responders (R) or nonresponders (NR) and develop an integrated microbiome prediction index. Unexpectedly, the NR-associated integrated index shows the strongest and most consistent signal using a random effects model and in a sensitivity and specificity analysis (
conclusionsOur analysis highlights the development of biomarkers for nonresponse, rather than response, in predicting ICI outcomes and suggests a new approach to identify patients who would benefit from microbiome-based interventions to improve response rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.